Despite the pandemic being very bad for local jobs and a handful of industries, it appears that venture capital continues to be strong throughout the spring and summer.

At the beginning of the month, we reported that a handful of Philly area companies have raised capital in the last month, but the fundraising news just keeps on coming.

Imvax, Inc., a Washington Square-based biotech firm, announced last week the closure of its $112 million Series C financing. The company’s neo-antigen immunotherapy, IGV-001, is being studied in patients with glioblastoma multiforme (GBM). The technology has the potential to advance care for patients with intractable solid tumor cancers, a company spokesperson said.

READ FULL ARTICLE HERE